Is CA125 useful in monitoring patients with platinum resistant ovarian cancer?

open access (pdf)


References:
1. Eisenhauer EA, Therasse P, Bogaerts et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer. 2009 Jan;45(2):228-47
2. Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J ClinOncol 2003;21: 187s-193s.
3. Rustin GJ, Vergote I, Eisenhauer E et al. Definitions for response and progression in ovarian cancerclinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).Int J Gynecol Cancer 2011; 21: 419-423.
4. K Lindemann, G Kristensen, M Raza Mirza, et al Poor concordance between CA-125 and RECIST at the time of disease progression inpatients with platinum-resistant ovarian cancer: Analysis of the AURELIA trial. Annals oncol in press.